Abbot receives FDA approval for its FlexAbility ablation catheter

The U.S. Food and Drug Administration has approved Abbot's FlexAbility ablation catheter.
"I am seeing an increasing number of patients with complex cardiac arrhythmias, which has created a strong need for advanced tools that can meet the needs of those patients" Dr. Jeffrey Winterfield, director of Ventricular Arrhythmia Service and associate professor of cardiac electrophysiology at the Medical University of South Carolina, said in a statement.
Abbot’s FlexAbility product was designed to improve versatility and precision during cardiac ablation procedures, which are used to treat atrial flutter. Atrial flutter is a type of irregular heartbeat. The FDA’s approval is a further step in the company’s electrophysiology portfolio expansion. Abbot’s portfolio in this arena providers various options for treating patients struggling with abnormal heart rhythms, or cardiac arrhythmias.
"We are continuing to innovate around the EnSite Precision cardiac mapping system to create an ablation portfolio that best supports physicians looking to tackle even the toughest cases," Dr. Srijoy Mahapatra, medical director of Abbott's electrophysiology business, said. "The introduction of the sensor enabled ablation catheter is delivering on that need. It offers the ability to engage the magnetic platform for enhanced precision, especially when physicians encounter a complex case."